Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

403
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
403
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

476
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

408
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
408
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
837

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for SSc cohort.

Arthritis research & therapy·2026
Same author

Effectiveness and safety of antiresorptive drugs in patients with systemic sclerosis-a retrospective monocentric study.

EULAR rheumatology open·2026
Same author

Skeletal effects of JAK1/2 inhibition versu<i>s</i> IL-6 receptor blockade in rheumatoid arthritis: a <i>post hoc</i> comparative cohort analysis based on two prospective observational studies.

Frontiers in pharmacology·2026
Same author

Serial CO₂ hand baths are associated with improved microvascular parameters and Raynaud-related symptoms in systemic sclerosis: A controlled feasibility study.

Microvascular research·2026
Same author

A case of human neoehrlichiosis with myocarditis in Germany: Clinical presentation and molecular diagnosis of the pathogen.

Ticks and tick-borne diseases·2026
Same author

Zeitschrift fur Rheumatologie·2026

Related Experiment Video

Updated: Feb 23, 2026

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

6.1K

Current Treatment Options for Osteoarthritis.

Walter Hermann1, Sevdalina Lambova2, Ulf Muller-Ladner1

  • 1Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik GmbH, Giessen, Germany.

Current Rheumatology Reviews
|September 7, 2017
PubMed
Summary

Osteoarthritis (OA) treatment remains challenging, with current drugs offering limited symptomatic relief. Emerging therapies targeting inflammation and bone metabolism show promise for disease modification and improved patient outcomes.

Keywords:
Osteoarthritisantiresoptive agentsbiologic agentsdisease-modifying drugspharmacological treatmenttreatment options.

More Related Videos

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.9K
Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.8K

Related Experiment Videos

Last Updated: Feb 23, 2026

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

6.1K
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.9K
Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.8K

Area of Science:

  • Rheumatology and Orthopedics
  • Pharmacology and Drug Discovery

Background:

  • Osteoarthritis (OA) is a prevalent degenerative joint disease causing significant disability and economic burden.
  • Current OA treatments primarily focus on symptom management, lacking disease-modifying capabilities.
  • Pathogenesis understanding has advanced, yet effective disease-modifying drugs are still unavailable.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for osteoarthritis.
  • To evaluate the efficacy of hydroxychloroquine, TNF-alpha blockers, and other novel agents in OA treatment.
  • To explore the potential of targeting bone metabolism and utilizing biologics for OA management.

Main Methods:

  • Review of recent clinical trials and studies on OA therapeutics.
  • Analysis of evidence for hydroxychloroquine (HCQ) in symptomatic hand OA.
  • Examination of research on TNF-alpha blockers and bone-targeting agents in OA.
  • Inclusion of studies on biologic agents like nerve growth factor-β inhibitors and platelet-rich plasma.

Main Results:

  • Hydroxychloroquine (HCQ) showed no superiority over placebo for pain relief or radiographic progression in hand OA.
  • Current evidence does not support the use of TNF-alpha blockers in OA, though specific subgroups may benefit.
  • Strontium renelate demonstrated a delay in joint space narrowing in knee OA.
  • Intraarticular platelet-rich plasma showed beneficial effects in knee and hip OA.

Conclusions:

  • Novel therapeutic approaches for OA are urgently needed, offering alternatives to conventional treatments.
  • Future OA therapies may include disease-modifying drugs targeting inflammation, bone metabolism, or utilizing biologics.
  • Further research is required to identify effective and safe treatments for OA, potentially revolutionizing patient care.